Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | APP | P05067 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30259471 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1GAAMAPTRAB9A | |
| SCHEMBL2486594 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1GAAMAPTRAB9A | |
| SCHEMBL30970380 | 0.91 | KDM4E (0.83) | KDM4EALDH1A1GAAMAPTRAB9A | |
| SCHEMBL6071506 | 0.91 | KDM4E (0.83) | KDM4EALDH1A1GAAMAPTRAB9A | |
| Methyl Piperate SCHEMBL2328493 | 0.90 | KDM4E (0.82) | KDM4EALDH1A1RAB9ASMN1; SMN2NPC1 | |
| Methyl Piperate SCHEMBL3244271 | 0.90 | KDM4E (0.82) | KDM4EALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL1232592 | 0.86 | KDM4E (0.75) | KDM4EALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1232591 | 0.86 | KDM4E (0.75) | KDM4EALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3565700 | 0.84 | KDM4E (0.72) | KDM4EALDH1A1GAAMAPTRAB9A | |
| SCHEMBL34468091 | 0.84 | KDM4E (0.72) | KDM4EALDH1A1GAAMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677647-A | Beta-bis-dioxolane anabasinic acid, preparation method and pharmaceutical application thereof | 吉林大学 | 2023-02-03 | — | — | CN | claimed |
| EP-2011495-A1 | Use of piperine and derivatives thereof for the therapy of neurological conditions | Sygnis Bioscience GmbH & Co. KG (DE) | 2009-01-07 | — | — | EP | claimed |
| EP-4626870-A1 | NONCOVALENT KEAP1-NRF2 SMALL-MOLECULE INHIBITORS | University of Copenhagen (DK) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024115641-A1 | NONCOVALENT KEAP1-NRF2 SMALL-MOLECULE INHIBITORS | UNIVERSITY OF COPENHAGEN (DK) | 2024-06-06 | — | — | WO | disclosed |
| CN-115677647-B | Beta-dioxolane emetic acid, preparation method and pharmaceutical application thereof | 吉林大学 | 2023-11-10 | — | — | CN | disclosed |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2023-09-12 | — | — | US | disclosed |
| CN-115677647-A | Beta-bis-dioxolane anabasinic acid, preparation method and pharmaceutical application thereof | 吉林大学 | 2023-02-03 | — | — | CN | disclosed |
| US-20210388017-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KP) | 2021-12-16 | — | — | US | disclosed |
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2019-07-11 | — | — | US | disclosed |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2019-05-14 | — | — | US | disclosed |
| US-10071980-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2018-09-11 | — | — | US | disclosed |
| US-7122561-B2 | Treatment of skin conditions | BTG INTERNATIONAL LIMITED (GB) | 2006-10-17 | — | — | US | disclosed |
| US-20040061142-A1 | Treatment of skin conditions | BTG INTERNATIONAL LIMITED | 2004-04-01 | — | — | US | disclosed |
| US-6680391-B2 | PIPERINE AND ANALOGUES OR DERIVATIVES FOR THE TREATMENT OF SKIN CONDITIONS TREATABLE BY STIMULATING MALENOCYTE PROLIFERATION, SUCH AS VITILGO, AND ALSO FOR SKIN CANCER | BTG INTERNATIONAL LIMITED (GB) | 2004-01-20 | — | — | US | disclosed |
| US-20020168369-A1 | Treatment of skin conditions | BTG INTERNATIONAL LIMITED | 2002-11-14 | — | — | US | disclosed |
| US-6346539-B1 | ADMINISTERING PIPERINE DERIVATIVE TO TREAT VITILIGO AND MELANOMA; STIMULATING MELANOCYTE PROLIFERATION; ANTICARCINOGENIC AGENTS | BTG INTERNATIONAL LIMITED (GB) | 2002-02-12 | — | — | US | disclosed |
| EP-0526535-B1 | CYCLIC HYDROXAMIC ACIDS AND THEIR USE | ORION YHTYMAE OY (FI) | 1995-09-27 | — | — | EP | disclosed |
| US-5356923-A | 1-hydroxy-4(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone and anti-hypertensive use thereof | ORION-YHTYMA OY (FI) | 1994-10-18 | — | — | US | disclosed |
| EP-0526535-A1 | CYCLIC HYDROXAMIC ACIDS AND THEIR USE. | ORION YHTYMAE OY (FI) | 1993-02-10 | — | — | EP | disclosed |
| WO-1991016303-A1 | CYCLIC HYDROXAMIC ACIDS AND THEIR USE | Orion-Yhtymä Oy (FI) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | KDM4E 3075/4885ALDH1A1 725/4885GAA 3294/4885 |
| US-20210388017-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | VIP, ANTXR2, TNFRSF9 | KDM4E 3750/4885ALDH1A1 4822/4885GAA 364/4885 |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | KDM4E 3260/4885ALDH1A1 755/4885GAA 3200/4885 |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | VIP, ANTXR2, TNFRSF9 | KDM4E 3750/4885ALDH1A1 4822/4885GAA 364/4885 |
| US-20020168369-A1 | Treatment of skin conditions | TYR, MC1R, MITF | KDM4E 643/4885ALDH1A1 502/4885GAA 435/4885 |
| US-10071980-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | KDM4E 3300/4885ALDH1A1 740/4885GAA 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.